Healthcare Economist November 10, 2023
According to a recent paper by Doshi et al. (2023), the answer is ‘yes‘! Why do people think otherwise?
Many people are concerned that there may not be a sustainable way for the private group insurance market, particularly in small self-insured firms, to cover gene therapies? If a firm—particularly a smaller, self-insured firm—gets one or two patients who needs gene therapies, this could ruin their profitability for reasons that have nothing to do with the underlying expense.
However, gene therapy is the perfect case for why insurance is needed:
After all, the primary goal of insurance, in theory, is converting a large, unexpected, unaffordable, but rare expense into a moderate insurance premium, by spreading an individual large expense over...
Today's Sponsors
Today's Sponsor